Showing results (111-120 of 185) with videos related to

Sort By:
Pageof 19
The Lancet. Oncology|May 18, 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G Richardson, Albert Oriol, Meral Beksac, et al.
Blood|February 13, 2008
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working GroupHeinz Ludwig, Brian G M Durie, Vanessa Bolejack, et al.
The Lancet. Haematology|October 19, 2016
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trialJesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 20, 2024
VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)Efstathios Kastritis, Meral Beksac, Sorina Nicoleta Badelita, et al.
Bone Marrow Transplantation|November 12, 2024
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMatjaz Sever, Joanna Drozd-Sokolowska, Luuk Gras, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 3, 2020
Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory MyelomaMeral Beksac, Yildiz Aydin, Hakan Goker, et al.
Science (New York, N.Y.)|August 27, 2011
The shaping of modern human immune systems by multiregional admixture with archaic humansLaurent Abi-Rached, Matthew J Jobin, Subhash Kulkarni, et al.
The Oncologist|March 29, 2011
Multiple myeloma treatment strategies with novel agents in 2011: a European perspectiveHeinz Ludwig, Meral Beksac, Joan Bladé, et al.
Blood|December 4, 2015
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatmentPaul G Richardson, Vânia T M Hungria, Sung-Soo Yoon, et al.
Haematologica|August 10, 2012
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trialsAntonio Palumbo, Anders Waage, Cyrille Hulin, et al.
Pageof 19